Outcome selection and reporting transparency in ClinicalTrials.gov-registered chronic spontaneous urticaria trials: a registry–publication linkage study

Clicks: 15
ID: 332577
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #162 of 238 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 238 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Chronic spontaneous urticaria/chronic idiopathic urticaria (CSU/CIU) trials increasingly evaluate biologics and targeted mast-cell therapies. Whether ClinicalTrials.gov-registered trials consistently capture patient-centred outcomes and disseminate results in a timely and linkable manner remains uncertain. Objectives To map registered outcome domains, patient-centred outcome breadth and reporting transparency among interventional CSU/CIU trials in ClinicalTrials.gov. Methods ClinicalTrials.gov was searched using three CSU/CIU-related queries, yielding 486 records and 168 unique NCT registrations after deduplication. Eligible interventional trials were coded for intervention category, trial purpose and nine registered outcome domains. A descriptive 0–8 patient-centred outcome score excluded safety. A stratified sample was independently recoded by a second author. Completed or terminated trials underwent manual registry–publication linkage, with primary and secondary publications distinguished and reporting assessed at 12, 24 and 36 months after primary completion using a fixed data lock of 1 June 2026. Results We included 128 eligible trials; 83 were completed or terminated. Disease activity/UAS7 (78.1%), itch/pruritus (65.6%) and wheals/hives (59.4%) were commonly registered, whereas urticaria control/UCT (28.1%), angioedema (30.5%), relapse/remission/rescue medication (24.2%) and explicit sleep/daily activity (7.8%) were less frequent. The mean patient-centred score was 3.37 (SD 1.98), and 20 trials (15.6%) scored at least 6. Independent second coding showed 90.4% agreement across 270 domain-level decisions. Among 83 completed/terminated trials, 32 (38.6%) had both posted results and a confirmed primary publication, whereas 15 (18.1%) had no qualifying public result identified. Any qualifying public result was available within 12, 24 and 36 months for 18.8%, 53.5% and 66.7% of trials with sufficient follow-up, respectively. Conclusions ClinicalTrials.gov-registered CSU/CIU trials show substantial heterogeneity in patient-centred outcome coverage. Distinguishing trial purpose, primary from secondary publications and reporting opportunity over time provides a more cautious assessment of the registered evidence base and highlights opportunities for more harmonised outcome selection and clearer result dissemination.
Reference Key
openalex_W7222470901 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yannan Liu, Ruhong Gao, Yongjun Peng, Wenli Ma, Fengxia Lian
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag450
URL
https://doi.org/10.1093/ced/llag450
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.